Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAT 1308

Next Previous
X
Search
Drug Profile

BAT 1308

Alternative Names: BAT-1308; Recombinant humanized anti PD-1 monoclonal antibody injection

Latest Information Update: 31 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bio-Thera Solutions
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Solid tumours
  • Phase II/III Endometrial cancer

Most Recent Events

  • 12 Apr 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT06341114)
  • 02 Apr 2024 Bio-Thera Solutions plans a phase I/II trial for Solid tumours (Late stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) (IV, Injection) (NCT06341114)
  • 20 Mar 2024 Phase-II/III clinical trials in Endometrial cancer (Combination therapy, First-line therapy, Late-stage disease, Recurrent) in China (IV) (NCT06321068)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top